GlaxoSmithKline

Commercial

Afisi Ismalia - Chief Invesitgator - GSKAlexander Ford - Corresponding Applicant - Adelphi Real WorldKieran Rothnie - Collaborator - GSKLucy Massey - Collaborator - Adelphi Real WorldQinggong Fu - Collaborator - GSKTheo Tritton - Collaborator - Adelphi Real WorldTim Holbrook - Collaborator - Adelphi Real WorldEileen Han - Collaborator - GSK

CPRD03

COVID-19 is a respiratory disease caused by infection with the virus SARS-CoV-2. The UK confirmed its first cases in January 2020 and as of the end of April 2021, had recorded more than 150,000 deaths where COVID-19 was listed on the death certificate. The widespread infection of SARS-CoV-2 in the UK has been considered an epidemic.

Aim: To assess the indirect and clinical impact of COVID-19 on patients with chronic obstructive pulmonary disease (COPD) and asthma in the years during and surrounding the UK COVID-19 epidemic, to inform and contextualize future research.

17/08/2021

Release